QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-liquidia-maintains-35-price-target

HC Wainwright & Co. analyst Andrew S. Fein reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $35 price target.

 liquidia-to-present-new-liq861-data-from-ascent-trial-at-chest-2025-annual-meeting

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiop...

 jefferies-assumes-liquidia-at-buy-announces-price-target-of-43

Jefferies analyst Amy Li assumes Liquidia (NASDAQ:LQDA) with a Buy rating and announces Price Target of $43.

 raymond-james-maintains-strong-buy-on-liquidia-raises-price-target-to-41

Raymond James analyst Ryan Deschner maintains Liquidia (NASDAQ:LQDA) with a Strong Buy and raises the price target from $33 ...

 wells-fargo-maintains-overweight-on-liquidia-raises-price-target-to-31

Wells Fargo analyst Tiago Fauth maintains Liquidia (NASDAQ:LQDA) with a Overweight and raises the price target from $25 to $31.

 why-is-liquidia-stock-trading-higher-on-tuesday

Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance...

 in-july-and-august-of-2025-liquidia-analyzed-interim-data-from-the-52-week-prospective-open-label-ascent-study-which-fully-enrolled-54-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild

Safety data and observed exploratory efficacy data was summarized for Week 8 and Week 16 timepoints. The tolerability profile o...

 earnings-preview-for-liquidia
Earnings Preview For Liquidia
08/11/2025 15:04:05

 wells-fargo-maintains-overweight-on-liquidia-raises-price-target-to-25

Wells Fargo analyst Tiago Fauth maintains Liquidia (NASDAQ:LQDA) with a Overweight and raises the price target from $23 to $25.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION